Exogenous hydrogen sulfide exerts proliferation/anti-apoptosis/angiogenesis/migration effects via amplifying the activation of NF-κB pathway in PLC/PRF/5 hepatoma cells

International Journal of Oncology

Volumn 46, Issue 5, 2015, Pages 2194-2204

  Zhen, Yulan ^a   Pan, Wanying ^b   Hu, Fen ^b   Wu, Hongfu ^a   Feng, Jianqiang ^c   Zhang, Ying ^a   Chen, Jingfu ^b  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Angiogenesis; Anti apoptisis; Hydrogen sulfide; Migration; NF B; PLC PRF 5 hepatoma cells; Proliferation

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; CASPASE 3; CYCLOOXYGENASE 2; CYSTATHIONINE BETA SYNTHASE; CYSTATHIONINE GAMMA LYASE; GELATINASE A; HYDROGEN SULFIDE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INORGANIC COMPOUND; PYRROLIDINE DITHIOCARBAMATE; SODIUM HYDROSULFIDE; SULFUR; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL COUNTER; CELL COUNTER KIT 8; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; ELECTRODE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE AMPLIFICATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; STAINING; TUMOR CELL LINE; WESTERN BLOTTING; CELL MOTION; CELL SURVIVAL; DRUG EFFECTS; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYDROGEN SULFIDE; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84925438423     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2914     Document Type: Article

References (79)

1. Nordenstedt H, White DL and El-Serag HB: The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 42 (Suppl 3): S206-S214, 2010.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
3. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
4. Yu MC and Yuan JM: Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 127 (Suppl 1): S72-S78, 2004.
5. Chuang SC, La Vecchia C and Boffetta P: Liver cancer: Descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett 286: 9-14, 2009.
6. Liang X, Bi S, Yang W, et al: Epidemiological serosurvey of hepatitis B in China - declining HBV prevalence due to hepatitis B vaccination. Vaccine 27: 6550-6557, 2009.
7. Liang H, Wang J, Xiao H, Wang D, Wei W, Qiao Y and Boffetta P: Estimation of cancer incidence and mortality attributable to alcohol drinking in China. BMC Public Health 10: 730, 2010.
8. Arsura M and Cavin LG: Nuclear factor-kappaB and liver carcinogenesis. Cancer Lett 229: 157-169, 2005.
9. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E and Ben-Neriah Y: NF-kappaB functions as a tumour promoter in inflammationassociated cancer. Nature 431: 461-466, 2004.
10. He G and Karin M: NF-κB and STAT3 - key players in liver inflammation and cancer. Cell Res 21: 159-168, 2011.
11. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J and Avila MA: Inflammation and liver cancer: New molecular links. Ann NY Acad Sci 1155: 206-221, 2009.
12. Baldwin AS Jr: Series introduction: The transcription factor NF-kappaB and human disease. J Clin Invest 107: 3-6, 2001.
13. Werner SL, Barken D and Hoffmann A: Stimulus specificity of gene expression programs determined by temporal control of IKK activity. Science 309: 1857-1861, 2005.
14. Curran JE, Weinstein SR and Griffiths LR: Polymorphic variants of NFKB1 and its inhibitory protein NFKBIA, and their involvement in sporadic breast cancer. Cancer Lett 188: 103-107, 2002.
15. Zhang P, Wei Q, Li X, Wang K, Zeng H, Bu H and Li H: A functional insertion/deletion polymorphism in the promoter region of the NFKB1 gene increases susceptibility for prostate cancer. Cancer Genet Cytogenet 191: 73-77, 2009.
16. Lo SS, Chen JH, Wu CW and Lui WY: Functional polymorphism of NFKB1 promoter may correlate to the susceptibility of gastric cancer in aged patients. Surgery 145: 280-285, 2009.
17. Yu Y, Liu H, Jin M, Zhang M, Pan Y, Zhang S, Li Q and Chen K: The joint association of REST and NFKB1 polymorphisms on the risk of colorectal cancer. Ann Hum Genet 76: 269-276, 2012.
18. Lin CW, Hsieh YS, Hsin CH, Su CW, Lin CH, Wei LH, Yang SF and Chien MH: Effects of NFKB1 and NFKBIA gene polymorphisms on susceptibility to environmental factors and the clinicopathologic development of oral cancer. PLoS One 7: e35078, 2012.
19. Gao J, Xu HL, Gao S, et al: Genetic polymorphism of NFKB1 and NFKBIA genes and liver cancer risk: A nested case-control study in Shanghai, China. BMJ Open 4: e004427, 2014.
20. 2S be the third endogenous gaseous transmitter? FASEB J 16: 1792-1798, 2002.
21. Guidotti TL: Hydrogen sulfide: Advances in understanding human toxicity. Int J Toxicol 29: 569-581, 2010.
22. Kilburn KH, Thrasher JD and Gray MR: Low-level hydrogen sulfide and central nervous system dysfunction. Toxicol Ind Health 26: 387-405, 2010.
23. Tan BH, Wong PT and Bian JS: Hydrogen sulfide: A novel signaling molecule in the central nervous system. Neurochem Int 56: 3-10, 2010.
24. Rong W, Kimura H and Grundy D: The neurophysiology of hydrogen sulfide. Inflamm Allergy Drug Targets 10: 109-117, 2011.
25. Kamoun P: Endogenous production of hydrogen sulfide in mammals. Amino Acids 26: 243-254, 2004.
26. Guo R, Wu K, Chen J, Mo L, Hua X, Zheng D, Chen P, Chen G, Xu W and Feng J: Exogenous hydrogen sulfide protects against doxorubicin-induced inflammation and cytotoxicity by inhibiting p38MAPK/NFκB pathway in H9c2 cardiac cells. Cell Physiol Biochem 32: 1668-1680, 2013.
27. Guo RM, Xu WM, Lin JC, Mo LQ, Hua XX, Chen PX, Wu K, Zheng DD and Feng JQ: Activation of the p38 MAPK/NF-κB pathway contributes to doxorubicin-induced inflammation and cytotoxicity in H9c2 cardiac cells. Mol Med Rep 8: 603-608, 2013.
28. El-Seweidy MM, Sadik NA and Shaker OG: Role of sulfurous mineral water and sodium hydrosulfide as potent inhibitors of fibrosis in the heart of diabetic rats. Arch Biochem Biophys 506: 48-57, 2011.
29. 2S against chemical hypoxia-induced injury in H9c2 cells. Mol Cell Biochem 362: 149-157, 2012.
30. 2S against chemical hypoxia-induced injury in H9c2 cardiac myocytes. Int J Mol Med 28: 397-403, 2011.
31. Chen SL, Yang CT, Yang ZL, Guo RX, Meng JL, Cui Y, Lan AP, Chen PX and Feng JQ: Hydrogen sulphide protects H9c2 cells against chemical hypoxia-induced injury. Clin Exp Pharmacol Physiol 37: 316-321, 2010.
32. Coletta C, Papapetropoulos A, Erdelyi K, et al: Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. Proc Natl Acad Sci USA 109: 9161-9166, 2012.
33. Cai WJ, Wang MJ, Moore PK, Jin HM, Yao T and Zhu YC: The novel proangiogenic effect of hydrogen sulfide is dependent on Akt phosphorylation. Cardiovasc Res 76: 29-40, 2007.
34. Papapetropoulos A, Pyriochou A, Altaany Z, et al: Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc Natl Acad Sci USA 106: 21972-21977, 2009.
35. Kimura H: Hydrogen sulfide: From brain to gut. Antioxid Redox Signal 12: 1111-1123, 2010.
36. Fiorucci S: Hydrogen sulfide: From physiology to pharmacology. Inflamm Allergy Drug Targets 10: 77-84, 2011.
37. Hegde A and Bhatia M: Hydrogen sulfide in inflammation: Friend or foe? Inflamm Allergy Drug Targets 10: 118-122, 2011.
38. Zhang H and Bhatia M: Hydrogen sulfide: A novel mediator of leukocyte activation. Immunopharmacol Immunotoxicol 30: 631-645, 2008.
39. Mok YY and Moore PK: Hydrogen sulphide is pro-inflammatory in haemorrhagic shock. Inflamm Res 57: 512-518, 2008.
40. Gong QH, Wang Q, Pan LL, Liu XH, Huang H and Zhu YZ: Hydrogen sulfide attenuates lipopolysaccharide-induced cognitive impairment: A pro-inflammatory pathway in rats. Pharmacol Biochem Behav 96: 52-58, 2010.
41. Zhang J, Sio SW, Moochhala S and Bhatia M: Role of hydrogen sulfide in severe burn injury-induced inflammation in mice. Mol Med 16: 417-424, 2010.
42. Szabo C, Coletta C, Chao C, Módis K, Szczesny B, Papapetropoulos A and Hellmich MR: Tumor-derived hydrogen sulfide, produced by cystathionine-β-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. Proc Natl Acad Sci USA 110: 12474-12479, 2013.
43. Pupo E, Pla AF, Avanzato D, Moccia F, Cruz JE, Tanzi F, Merlino A, Mancardi D and Munaron L: Hydrogen sulfide promotes calcium signals and migration in tumor-derived endothelial cells. Free Radic Biol Med 51: 1765-1773, 2011.
44. Du SX, Xiao J, Guan F, Sun LM, Wu WS, Tang H, Du JB, Tang CS and Jin HF: Predictive role of cerebrospinal fluid hydrogen sulfide in central nervous system leukemia. Chin Med J (Engl) 124: 3450-3454, 2011.
45. Levine J, Ellis CJ, Furne JK, Springfield J and Levitt MD: Fecal hydrogen sulfide production in ulcerative colitis. Am J Gastroenterol 93: 83-87, 1998.
46. Rose P, Moore PK, Ming SH, Nam OC, Armstrong JS and Whiteman M: Hydrogen sulfide protects colon cancer cells from chemopreventative agent beta-phenylethyl isothiocyanate induced apoptosis. World J Gastroenterol 11: 3990-3997, 2005.
47. Cai WJ, Wang MJ, Ju LH, Wang C and Zhu YC: Hydrogen sulfide induces human colon cancer cell proliferation: Role of Akt, ERK and p21. Cell Biol Int 34: 565-572, 2010.
48. 2S production in colon cancer cells. Antioxid Redox Signal 12: 1101-1109, 2010.
49. 2S? PLoS One 6: e20525, 2011.
50. Murata T, Sato T, Kamoda T, Moriyama H, Kumazawa Y and Hanada N: Differential susceptibility to hydrogen sulfide-induced apoptosis between PHLDA1-overexpressing oral cancer cell lines and oral keratinocytes: Role of PHLDA1 as an apoptosis suppressor. Exp Cell Res 320: 247-257, 2014.
51. Chattopadhyay M, Kodela R, Olson KR and Kashfi K: NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. Biochem Biophys Res Commun 419: 523-528, 2012.
52. Lee ZW, Zhou J, Chen CS, Zhao Y, Tan CH, Li L, Moore PK and Deng LW: The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer effects in vitro and in vivo. PLoS One 6: e21077, 2011.
53. Xu W, Wu W, Chen J, Guo R, Lin J, Liao X and Feng J: Exogenous hydrogen sulfide protects H9c2 cardiac cells against high glucoseinduced injury by inhibiting the activities of the p38 MAPK and ERK1/2 pathways. Int J Mol Med 32: 917-925, 2013.
54. Kashfi K: Anti-cancer activity of new designer hydrogen sulfidedonating hybrids. Antioxid Redox Signal 20: 831-846, 2014.
55. Shi S, Li QS, Li H, Zhang L, Xu M, Cheng JL, Peng CH, Xu CQ and Tian Y: Anti-apoptotic action of hydrogen sulfide is associated with early JNK inhibition. Cell Biol Int 33: 1095-1101, 2009.
56. Rinaldi L, Gobbi G, Pambianco M, Micheloni C, Mirandola P and Vitale M: Hydrogen sulfide prevents apoptosis of human PMN via inhibition of p38 and caspase 3. Lab Invest 86: 391-397, 2006.
57. Holwerda KM, Burke SD, Faas MM, et al: Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factor. J Am Soc Nephrol 25: 717-725, 2014.
58. Polhemus DJ, Kondo K, Bhushan S, Bir SC, Kevil CG, Murohara T, Lefer DJ and Calvert JW: Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis. Circ Heart Fail 6: 1077-1086, 2013.
59. Köhn C, Dubrovska G, Huang Y and Gollasch M: Hydrogen sulfide: Potent regulator of vascular tone and stimulator of angiogenesis. Int J Biomed Sci 8: 81-86, 2012.
60. Bir SC, Kolluru GK, McCarthy P, Shen X, Pardue S, Pattillo CB and Kevil CG: Hydrogen sulfide stimulates ischemic vascular remodeling through nitric oxide synthase and nitrite reduction activity regulating hypoxia-inducible factor-1α and vascular endothelial growth factor-dependent angiogenesis. J Am Heart Assoc 1: e004093, 2012.
61. 2S- targeting receptor protein kinase with its novel Cys1045-Cys1024 disulfide bond serving as a specific molecular switch for hydrogen sulfide actions in vascular endothelial cells. Antioxid Redox Signal 19: 448-464, 2013.
62. Leung WK, To KF, Go MY, Chan KK, Chan FK, Ng EK, Chung SC and Sung JJ: Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma. Int J Oncol 23: 1317-1322, 2003.
63. Jones JL, Shaw JA, Pringle JH and Walker RA: Primary breast myoepithelial cells exert an invasion-suppressor effect on breast cancer cells via paracrine down-regulation of MMP expression in fibroblasts and tumour cells. J Pathol 201: 562-572, 2003.
64. Li C, Li F, Zhao K, Yao J, Cheng Y, Zhao L, Li Z, Lu N and Guo Q: LFG-500 inhibits the invasion of cancer cells via downregulation of PI3K/AKT/NF-κB signaling pathway. PLoS One 9: e91332, 2014.
65. Puzovic V, Brcic I, Ranogajec I and Jakic-Razumovic J: Prognostic values of ETS-1, MMP-2 and MMP-9 expression and co-expression in breast cancer patients. Neoplasma 61: 439-446, 2014.
66. Ruan M, Zhang Z, Li S, Yan M, Liu S, Yang W, Wang L and Zhang C: Activation of Toll-like receptor-9 promotes cellular migration via up-regulating MMP-2 expression in oral squamous cell carcinoma. PLoS One 9: e92748, 2014.
67. 2S inhibition of chemical hypoxia-induced proliferation of HPASMCs is mediated by the upregulation of COX-2/PGI2. Int J Mol Med 33: 359-366, 2014.
68. Ang SF, Sio SW, Moochhala SM, MacAry PA and Bhatia M: Hydrogen sulfide upregulates cyclooxygenase-2 and prostaglandin E metabolite in sepsis-evoked acute lung injury via transient receptor potential vanilloid type 1 channel activation. J Immunol 187: 4778-4787, 2011.
69. Terzuoli E, Meini S, Cucchi P, Catalani C, Cialdai C, Maggi CA, Giachetti A, Ziche M and Donnini S: Antagonism of bradykinin B2 receptor prevents inflammatory responses in human endothelial cells by quenching the NF-κB pathway activation. PLoS One 9: e84358, 2014.
70. Tsagaraki I, Phenekos C, Tsilibary E and Tzinia A: Calciton-ininduced NF-κB activation up-regulates fibronectin expression in MG63 osteosarcoma cells. Anticancer Res 33: 4901-4906, 2013.
71. Hsu CJ, Wu MH, Chen CY, Tsai CH, Hsu HC and Tang CH: AMP-activated protein kinase activation mediates CCL3-induced cell migration and matrix metalloproteinase-2 expression in human chondrosarcoma. Cell Commun Signal 11: 68, 2013.
72. Son SW, Kim HG, Han JM, Lee JS, Choi MK, Lee JS and Son CG: Anti-melanoma activity of Cynanchi atrat i Radix is mediated by regulation of NF-kappa B activity and pro-apoptotic proteins. J Ethnopharmacol 153: 250-257, 2014.
73. Jana D, Sarkar DK, Ganguly S, Saha S, Sa G, Manna AK, Banerjee A and Mandal S: Role of cyclooxygenase 2 (COX-2) in prognosis of breast cancer. Indian J Surg Oncol 5: 59-65, 2014.
74. Wu X, Cai M, Ji F and Lou LM: The impact of COX-2 on invasion of osteosarcoma cell and its mechanism of regulation. Cancer Cell Int 14: 27, 2014.
75. Xu K, Wang L and Shu HK: COX-2 overexpression increases malignant potential of human glioma cells through Id1. Oncotarget 5: 1241-1252, 2014.
76. Dong X, Li R, Xiu P, et al: Meloxicam executes its antitumor effects against hepatocellular carcinoma in COX-2- dependent and -independent pathways. PLoS One 9: e92864, 2014.
77. Tegeder I, Niederberger E, Israr E, Gühring H, Brune K, Euchenhofer C, Grösch S and Geisslinger G: Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen. FASEB J 15: 2-4, 2001.
78. Seo KW, Coh YR, Rebhun RB, et al : Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines. Res Vet Sci pii: S0034-5288: 00051-00054, 2014.
79. Sui W, Zhang Y, Wang Z, Wang Z, Jia Q, Wu L and Zhang W: Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H22 murine hepatocarcinoma model. Oncol Rep 31: 2252-2260, 2014.